English
Jyong Biotech Ltd.
EDGARMarket value is not computed: this company’s US price is per depositary share, not per ordinary share.
5 filing records in this dataset, filed from 2023-08-17 to 2026-05-15. Reported financial figures are available; chart coverage varies by period.
Holdings and insider activity
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
This issuer has insider filings in the store, but no transaction in this window or code group.
5% holders (Schedule 13D and 13G)
- Perfect Minds Co., Ltd 33.34% SCHEDULE 13D 06/16/2025
- Innovation Global Group Limited 33.34% SCHEDULE 13D 06/16/2025
- Unity Trust Limited as trustee of The Innovation Trust 33.34% SCHEDULE 13D 06/16/2025
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- 2.12 million USD
Exact inputs and evidence
2124000 USD
- Long-term debt including current maturities: 2124000 USD Source
- Shares outstanding
- 76 million shares Source
Exact value
76028000 shares
Reported share-count change
3.64% · 2.67 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-05-15.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 2 of 11 periods available· newest 2025-12-31
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- cash and cash equivalents: No compatible figures in this window
- Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 1.65 millionPrior period
−USD 3.02 million
–
Current period
−USD 4.67 million
–
Exact inputs and evidence
-4671000 − -3019000 = -1652000 USD
-3019000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-4671000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 583,000Prior period
−USD 3.62 million
–
Current period
−USD 3.04 million
–
Exact inputs and evidence
-3041000 − -3624000 = 583000 USD
-3624000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-3041000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 4.4 million Exact valueExact value: -4400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.6 million Exact valueExact value: -2601000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 3.02 million Exact valueExact value: -3019000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.62 million Exact valueExact value: -3624000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 4.67 million Exact valueExact value: -4671000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.04 million Exact valueExact value: -3041000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
5 filings · 116 latest values · 116 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001954488, 1954488, MENS, edgar:1954488
Also known as Jyong Biotech Ltd.